Serina Therapeutics, Inc. (SER) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 130K | 0 | -14K | 14K | 0 | 5K | 3.09M | 29K | 7K |
| Revenue Growth % | - | 100% | -100% | - | -100% | -100.45% | -51.72% | -100% | -83.33% | 38487.5% | 222.22% | -41.67% |
| Cost of Goods Sold | 18K | 0 | 0 | 16K | 0 | 0 | 0 | 0 | 25K | 6K | 53K | 18K |
| COGS % of Revenue | - | - | - | 12.31% | - | - | - | - | 500% | 0.19% | 182.76% | 257.14% |
| Gross Profit | -18K | 0 | 0 | 114K | 0 | -14K | 14K | 0 | -20K | 3.08M | -24K | -11K |
| Gross Margin % | - | - | - | 87.69% | - | 100% | 100% | - | -400% | 99.81% | -82.76% | -157.14% |
| Gross Profit Growth % | - | 100% | -100% | - | 100% | -100.45% | 158.33% | 100% | -217.65% | 11950% | 17.24% | 59.26% |
| Operating Expenses | 6.26M | 6.21M | 6.39M | 5.68M | 5.86M | 5.54M | 5.33M | 3.87M | 2.3M | 2.84M | 1.44M | 934K |
| OpEx % of Revenue | - | - | - | 4368.46% | - | -39535.71% | 38042.86% | - | 46020% | 92% | 4962.07% | 13342.86% |
| Selling, General & Admin | 3.08M | 2.81M | 2.74M | 2.54M | 2.91M | 3.17M | 2.91M | 2.32M | 1.22M | 1.93M | 889K | 473K |
| SG&A % of Revenue | - | - | - | 1956.15% | - | -22642.86% | 20792.86% | - | 24400% | 62.62% | 3065.52% | 6757.14% |
| Research & Development | 3.2M | 3.4M | 3.65M | 3.15M | 2.95M | 2.37M | 2.42M | 1.59M | 1.11M | 907K | 550K | 479K |
| R&D % of Revenue | - | - | - | 2424.62% | - | -16892.86% | 17250% | - | 22120% | 29.38% | 1896.55% | 6842.86% |
| Other Operating Expenses | 0 | 0 | 0 | -16K | 0 | 0 | 0 | -51K | -25K | 0 | 0 | -18K |
| Operating Income | -6.28M | -6.21M | -6.39M | -5.57M | -5.86M | -5.55M | -5.31M | -3.87M | -2.32M | 241K | -1.46M | -945K |
| Operating Margin % | - | - | - | -4280.77% | - | 39635.71% | -37942.86% | - | -46420% | 7.81% | -5044.83% | -13500% |
| Operating Income Growth % | -7.2% | -11.86% | -20.33% | -43.95% | -152.39% | -2402.49% | -263.09% | -309.1% | -141.27% | 113.52% | 5.61% | 40.6% |
| EBITDA | -6.26M | -6.18M | -6.38M | -5.55M | -5.84M | -5.49M | -5.26M | -3.81M | -2.3M | 247K | -1.41M | -928K |
| EBITDA Margin % | - | - | - | -4268.46% | - | 39235.71% | -37542.86% | - | -45920% | 8% | -4862.07% | -13257.14% |
| EBITDA Growth % | -7.21% | -12.56% | -21.31% | -45.68% | -154.4% | -2323.89% | -272.77% | -310.45% | -141.94% | 114.12% | 7.05% | 40.44% |
| D&A (Non-Cash Add-back) | 18K | 24K | 16K | 16K | 17K | 56K | 56K | 57K | 25K | 6K | 53K | 17K |
| EBIT | -6.28M | -3.12M | -4.59M | -6.45M | -4.82M | -2.73M | 1.4M | 5.42M | -14.83M | 1.23M | 1.85M | 916K |
| Net Interest Income | 189K | -198K | -6K | -9K | 0 | -17K | -16K | -242K | -99K | -176K | -100K | -108K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | -189K | 198K | 6K | 9K | 0 | 17K | 16K | 242K | 99K | 176K | 100K | 108K |
| Other Income/Expense | -611K | 2.89M | 1.8M | -897K | 1.04M | 2.8M | 6.7M | 9.04M | -12.69M | 810K | 3.21M | 1.75M |
| Pretax Income | -6.89M | -3.32M | -4.59M | -6.46M | -4.82M | -2.75M | 1.38M | 5.18M | -15.02M | 1.05M | 1.75M | 808K |
| Pretax Margin % | - | - | - | -4970.77% | - | 19657.14% | 9878.57% | - | -300300% | 34.05% | 6041.38% | 11542.86% |
| Income Tax | 7K | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.1% | -0.54% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.9M | -3.34M | -4.58M | -6.45M | -4.81M | -2.74M | 1.41M | 5.2M | -15.02M | 1.05M | 1.75M | 808K |
| Net Margin % | - | - | - | -4960% | - | 19571.43% | 10071.43% | - | -300300% | 34.05% | 6041.38% | 11542.86% |
| Net Income Growth % | -43.32% | -21.75% | -425.18% | -223.9% | 67.95% | -360.7% | -19.52% | 544.06% | -1005.61% | 138.88% | 171.95% | 130.86% |
| Net Income (Continuing) | -6.9M | -3.34M | -4.59M | -6.46M | -4.82M | -2.75M | 1.38M | 5.18M | -15.02M | 1.05M | 1.75M | 808K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -166K | -156K | -142K | -133K | -54K | -30K | 0 | 0 | -109K | -121K |
| EPS (Diluted) | -0.58 | -0.31 | -0.44 | -0.64 | -0.49 | -0.25 | 0.13 | 0.51 | -5.38 | 0.44 | 0.23 | -0.24 |
| EPS Growth % | -18.37% | -24% | -438.46% | -225.49% | 90.89% | -156.82% | -43.48% | 312.5% | -2790% | 117.53% | 110.18% | 90.12% |
| EPS (Basic) | -0.58 | -0.31 | -0.44 | -0.64 | -0.49 | -0.31 | 0.16 | 0.61 | -5.38 | 0.44 | 0.80 | 0.37 |
| Diluted Shares Outstanding | 12.05M | 10.19M | 10.34M | 10M | 9.76M | 10.75M | 10.75M | 10.16M | 2.79M | 1.08M | 7.58M | 1.08M |
| Basic Shares Outstanding | 12.05M | 10.19M | 10.34M | 10M | 9.76M | 8.85M | 8.85M | 8.51M | 2.79M | 1.08M | 2.19M | 1.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |